Adma Biologics reported $69.54M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Adma Biologics USD 69.54M 13.05M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
Minerva Neurosciences USD 2.29M 381K Dec/2025
Novavax USD 459.95M 30.08M Dec/2025
Omeros USD 85.5M 2.28M Jun/2025
Takeda JPY 2.61T 470.53B Dec/2025